B
Brain Tunnelgenix Technologies
Produces non-invasive and continuous temperature measurement devices
About Brain Tunnelgenix Technologies
Brain Tunnelgenix Technologies (BTT) Corp. is a medical technology company founded in 2006, centered on the discovery of the Brain Temperature Tunnel (BTT™). This discovery was made by Dr. M. Marc Abreu, a medical doctor and former faculty member at Yale University School of Medicine and Harvard Medical School. Dr. Abreu's research in brain thermodynamics led to the identification of a noninvasive pathway to measure brain temperature continuously. This was a significant development, as it historically required invasive methods.
The company's core technology is based on this biological patent for the BTT, a thermophysical pathway located between the eye and eyebrow that allows for the unimpeded transfer of thermal energy from the brain. BTT Corp. develops and licenses patented products that utilize this tunnel to track and modulate brain temperature. Its flagship product, the Abreu BTT™ 700 System, received FDA 510(k) clearance in 2010. This computer-based system uses a sensor placed on the skin over the BTT to monitor temperature continuously and noninvasively, intended for use during surgical procedures, in recovery rooms, and for intensive care and general patient monitoring. The company operates on a business model that includes the sale of its medical devices and the development of subscription services for managing and researching various health conditions.
The firm's primary clients are healthcare professionals, researchers, and medical institutions. BTT is also exploring applications in other markets such as sports, military, and general wellness. The company's technology is being applied to develop diagnostics and therapies for a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and ALS. By modulating brain thermodynamics, the company aims to induce heat shock proteins that could help refold misfolded proteins, a common factor in many neurodegenerative diseases. In June 2022, the company secured $29.3 million in venture funding to expand its research and development efforts.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 59.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2022 | $29M | $117M | Oklahoma Rock Holdings, LLC | ↗ |
| LATE VCOther financing | Jan 2022 | $29M | $117M | Undisclosed | — |
Growth signals
Brain Tunnelgenix Technologies's team grew 200% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Brain Tunnelgenix Technologies in the Bridgeport ecosystem
The Brain Tunnelgenix Technologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- OLOklahoma Rock Holdings, LLC
Other known investors1 additional known investor
Yale University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Brain Tunnelgenix Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Brain Tunnelgenix Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








